Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
Public ClinicalTrials.gov record NCT05794139. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy
Study identification
- NCT ID
- NCT05794139
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- NMD Pharma A/S
- Industry
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Interventions
- NMD670 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 20, 2023
- Primary completion
- May 10, 2026
- Completion
- May 17, 2026
- Last update posted
- Jun 2, 2026
2023 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA David Geffen School Of Medicine - Neurology | Los Angeles | California | 90095 | — |
| Stanford University Medical Center | Palo Alto | California | 94304 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| The Johns Hopkins Medicine, Spinal Muscular Atrophy Center | Baltimore | Maryland | 21287 | — |
| Roy Blunt NextGen Precision Health Institute | Columbia | Missouri | 65212 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Rare Disease Research - Raleigh-Durham | Hillsborough | North Carolina | 27278 | — |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Neurology Rare Disease Center | Denton | Texas | 76208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05794139, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 2, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05794139 live on ClinicalTrials.gov.